Citations

Clear

9383 citation(s) found for "Thomas, PS".

Activity enhances dopaminergic long-duration response in Parkinson disease
Kang, Un Jung , Auinger, Peggy , Fahn, Stanley, Oakes, David , Shoulson, Ira , Kieburtz, Karl, Rudolph, Alice, Seibyl, John , Olanow, C. Warren , Tanner, Caroline M., Schifitto, Giovanni , Zhao, Hongwei , Reyes, Lydia, Shinaman, Aileen, Comella, Cynthia L., Blasucci, Lucia M., Samanta, Johan, Stacy, Mark, Williamson, Kelli, Harrigan, Mary, Greene, Paul, Ford, Blair, Moskowitz, Carol, Truong, Daniel , Pathak, Mayank , Jankovic, Joseph, Ondo, William G. , Atassi, Farah, Hunter, Christine , Jacques, Carol, Lannon, Margaret C., Russell, David , Jennings, Danna , Fussell, B., Schwarzschild, Michael A. , Growdon, John H., Tennis, Marsha, Gauthier, Serge , Panisset, Michel , Hall, Jean, Gancher, Stephen T., Hammerstad, John P., Stone, Claudia, Alexander-Brown, Barbara, Molho, Eric , Brown, Diane, Evans, Sharon, Manyam, Bala V., Simpson, Patricia , Wulbrecht, Brian, Whetteckey, Jacqueline, Roberts, Ted E, King, Pamela, Zesiewicz, Theresa A. , Gauger, Lisa, Trugman, Joel M. , Wooten, G. Frederick, Rost‐Ruffner, Elke, Suchowersky, Oksana , Ranawaya, Ranjit, Wood, Susan M. , Pantella, Carol , Kurlan, Roger, Richard, Irene Hegeman, Pearson, N. Shirlene, Caviness, John N., Adler, Charles, Lind, Marlene, Siderowf, Andrew , Colcher, Amy, Lloyd, Mary, Weiner, William J., Shulman, Lisa M. , Koller, William C., Lyons, Kelly , Feldman, Robert G., Ellias, Samuel A., Thomas, Cathi-Ann, Juncos, Jorge L., Watts, Ray L., Partlow, Anna, Tetrud, James W., Togasaki, Daniel M., Stewart, Tracy, Mark, Margery H., Sage, Jacob I., Caputo, Debbie, Gould, Harry J. , Rao, Jayaraman, McKendrick, A. D., Brin, Mitchell F. , Danisi, Fabio , Benabou, Reina, Hubble, Jean, Paulson, George W., Reider, Carson, Birnbaum, Alex, So, Julie , Dubinsky, Richard , Uitti, Ryan J. , Turk, Margaret F., Rottenberg, David A., Hansen, Joy, Ramos, Serrano, Waters, Cheryl , Lew, Mark, Welsh, Mickie, Kawai, Connie, OʼBrien, Christopher , Kumar, Rajeev , Seeberger, Lauren , Judd, Deborah, Mendis, Tilak, Grimes, David A. , Sutherland, Laura, Dawson, Ted M. , Reich, Stephen G. , Frey, Kirk A. , Wernette, K., Marek, Kenneth , Lang, Anthony E. , Goetz, Christopher G. , Jankovic, Joseph, Friedman, Joseph H. , Standaert, David G. , Factor, Stewart Alan , Clark, Jeffrey N. , Martin, W. R. Wayne , Hauser, Robert A. , Perlmutter, Joel S. , Racette, Brad A. , Simuni, Tanya , Saint‐Hilaire, Marie , Miyasaki, Janis M. , Johnston, Lisa , Pahwa, Rajesh , Wszołek, Zbigniew K. , Tuite, Paul , Barclay, Corlane , Dunlop, Rebecca A. , Albin, Roger L.

Mayo Clinic

Neurology | March 30, 2012 | Volume: 78 | Issue: 15 | Pages: 1146-1149

10.1212/wnl.0b013e31824f8056 | PMID 22459675 Get It

Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic KRAS Mutation Status among Older Women
Limsui, David, Vierkant, Robert A. , Tillmans, Lori S. , Wang, Alice H., Lynch, Charles F. , Anderson, Kristin E. , French, Amy J. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Cerhan, James R. , Limburg, Paul J. , Slager, Susan L. , Cerhan, James R , Vierkant, Robert A , Haile, Robert W , Potter, John D

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 29, 2012 | Volume: 21 | Issue: 4 | Pages: 681-684

10.1158/1055-9965.epi-11-1168 | PMID 22337533 Get It

Abstract Background: Postmenopausal hormone (PMH) therapy represents a controversial colorectal cancer (CRC) preventive intervention. Because colorectal carcinogenesis is a heterogeneous process, we evaluated associations between PMH therapy and incident CRC in relation to KRAS mutation status in a population-based cohort of older women [Iowa Women's Health Study (IWHS)]. Methods: The IWHS enrolled 41,836 randomly selected women, ages 55 to 69 years, in 1986. PMH therapy and other exposure data were recorded at baseline. Tissue samples from prospectively identified CRC cases (n = 507) were analyzed for somatic KRAS mutations (exon 2, codons 12 and 13). Multivariable Cox regression models were fit to estimate relative risks (RR) and 95% confidence intervals (CI). Results: PMH therapy (ever vs. never) was inversely associated with KRAS mutation–negative (RR = 0.83; 95% CI, 0.66–1.06; P = 0.14) and KRAS mutation–positive (RR = 0.82; 95% CI, 0.58–1.16; P = 0.27) tumors, although the observed risk estimates were not statistically significant. When anatomic subsite was additionally considered, the strongest association was found for KRAS mutation–negative, distal colorectal tumors (RR = 0.64; 95% CI, 0.43–0.96; P = 0.03). Conclusions: To our knowledge, we provide the first report of KRAS-defined CRC risks associated with PMH therapy. These data suggest that PMH therapy may reduce CRC risk through mechanisms beyond KRAS mutation status but might provide greater benefits for KRAS mutation–negative than mutation-positive tumors (at least in the distal colorectum). Impact: Findings from this prospective cohort study provide novel insights about the molecular biology of PMH therapy–related CRC risk reduction. Cancer Epidemiol Biomarkers Prev; 21(4); 681–4. ©2012 AACR.
RhoA as a Mediator of Clinically Relevant Androgen Action in Prostate Cancer Cells
Schmidt, Lucy J., Duncan, Kelly , Yadav, Neelu, Regan, Kevin M., Verone, Alissa R., Lohse, Christine M. , Pop, Elena , Wilding, Gregory E. , Mohler, James L. , Sebo, Thomas J., Tindall, Donald J., Heemers, Hannelore V. , Attwood, Kristopher M.

Mayo Clinic

Molecular Endocrinology | March 29, 2012 | Volume: 26 | Issue: 5 | Pages: 716-735

10.1210/me.2011-1130 | PMID 22456196 Get It

AbstractRecently, we have identified serum response factor (SRF) as a mediator of clinically relevant androgen receptor (AR) action in prostate cancer (PCa). Genes that rely on SRF for androgen responsiveness represent a small fraction of androgen-regulated genes, but distinguish benign from malignant prostate, correlate with aggressive disease, and are associated with biochemical recurrence. Thus, understanding the mechanism(s) by which SRF conveys androgen regulation to its target genes may provide novel opportunities to target clinically relevant androgen signaling. Here, we show that the small GTPase ras homolog family member A (RhoA) mediates androgen-responsiveness of more than half of SRF target genes. Interference with expression of RhoA, activity of the RhoA effector Rho-associated coiled-coil containing protein kinase 1 (ROCK), and actin polymerization necessary for nuclear translocation of the SRF cofactor megakaryocytic acute leukemia (MAL) prevented full androgen regulation of SRF target genes. Androgen treatment induced RhoA activation, increased the nuclear content of MAL, and led to MAL recruitment to the promoter of the SRF target gene FHL2. In clinical specimens RhoA expression was higher in PCa cells than benign prostate cells, and elevated RhoA expression levels were associated with aggressive disease features and decreased disease-free survival after radical prostatectomy. Overexpression of RhoA markedly increased the androgen-responsiveness of select SRF target genes, in a manner that depends on its GTPase activity. The use of isogenic cell lines and a xenograft model that mimics the transition from androgen-stimulated to castration-recurrent PCa indicated that RhoA levels are not altered during disease progression, suggesting that RhoA expression levels in the primary tumor determine disease aggressiveness. Androgen-responsiveness of SRF target genes in castration-recurrent PCa cells continued to rely on AR, RhoA, SRF, and MAL and the presence of intact SRF binding sites. Silencing of RhoA, use of Rho-associated coiled-coil containing protein kinase 1 inhibitors, or an inhibitor of SRF-MAL interaction attenuated (androgen-regulated) cell viability and blunted PCa cell migration. Taken together, these studies demonstrate that the RhoA signaling axis mediates clinically relevant AR action in PCa.
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2
Gaudet, Mia M. , Antoniou, Antonis C. , Ramus, Susan J. , Kuchenbaecker, Karoline , Soucy, Penny, Chen, Xiaoqing, Kirchhoff, Tomas , McGuffog, Lesley, Barrowdale, Daniel , Healey, Sue, Sinilnikova, Olga M., Andrulis, Irene L. , Özçelik, Hilmi, Mulligan, Anna Marie , Thomassen, Mads , Gerdes, Anne‐Marie , Jensen, Uffe Birk , Skytte, Anne‐Bine , Kruse, Torben A., Caligo, Maria A. , Wachenfeldt, Anna von , Barbany, Gisela , Loman, Niklas, Soller, Maria , Ehrencrona, Hans , Karlsson, Per , Nathanson, Katherine L. , Rebbeck, Timothy R., Jakubowska, Anna , Lubiński, Jan , Jaworska, Katarzyna, Durda, Katarzyna, Złowocka, Elżbieta, Huzarski, Tomasz , Byrski, Tomasz , Cybulski, Cezary, Górski, Bohdan , Osório, Ana , Durán, M. , Tejada, María‐Isabel , Hamann, Ute, Hogervorst, Frans B.L., Os, Theo A. van, Leeuwen, Flora E. van , Meijers‐Heijboer, Hanne , Blok, Marinus J. , Kets, Marleen, Hooning, Maartje J. , Oldenburg, Rogier A., Ausems, Margreet G.E.M. , Peock, Susan, Frost, Debra, Ellis, Steve D., Platte, Radka, Fineberg, Elena, Evans, D. Gareth , Jacobs, Chris , Eeles, Rosalind A. , Adlard, Julian , Davidson, Rosemarie, Eccles, Diana M., Cole, Trevor, Paterson, Joan, Brewer, Carole, Douglas, Fiona, Hodgson, Shirley V. , Walker, Lisa, Porteous, Mary, Kennedy, M. John, Side, Lucy, Bove, Betsy, Fassy-Colcombet, Marion, Castéra, Laurent , Cornelis, François, Mazoyer, Sylvie , Léoné, Mélanie, Boutry‐Kryza, Nadia, Paillerets, Brigitte Bressac–de , Coupier, Isabelle, Delnatte, Capucine, Akloul, Linda, Lynch, Henry T., Snyder, Carrie, Daly, Mary B., Terry, Mary Beth , John, Esther M. , Miron, Alexander, Southey, Melissa C. , Goldgar, David E., Singer, Christian F., Rappaport, Christine , Tea, Muy‐Kheng M., Fink-Retter, Anneliese, Hansen, Thomas van Overeem , Nielsen, Finn C., Arason, Aðalgeir , Vijai, Joseph , Shah, Sohela, Sarrel, Kara , Piedmonte, Marion, Phillips, Kelly, Basil, Jack, Rubinstein, Wendy S. , Boggess, John F., Wakeley, Katie, Montagna, Marco , Imyanitov, Evgeny N., Janavičius, Ramūnas , Lázaro, Conxi , Blanco, Ignacio , Feliubadaló, Lídia , Brunet, Joan , Gayther, Simon A. , Odunsi, Kunle , Walsh, Christine , Oláh, Edith , Teo, Soo‐Hwang , Ganz, Patricia A. , Beattie, Mary, Rensburg, Elizabeth J. van , Dorfling, Cecelia M., Dı́ez, Orland , Kwong, Ava , Schmutzler, Rita K., Wappenschmidt, Barbara, Engel, Christoph , Meindl, Alfons , Ditsch, Nina , Arnold, Norbert , Heidemann, Simone , Niederacher, Dieter , Preisler‐Adams, Sabine, Gadzicki, Dorothea, Varon-Mateeva, Raymonda, Deißler, Helmut , Gehrig, Andrea, Sutter, Christian , Kast, Karin, Fiebig, Britta, Heinritz, Wolfram, Caldes, Trinidad, Hoya, Miguel de la , Muranen, Taru , Nevanlinna, Heli , Spurdle, Amanda B. , Ding, Yuan Chun , Lindor, Noralane M. , Fredericksen, Zachary, Pankratz, V. Shane , Peterlongo, Paolo , Manoukian, Siranoush , Peissel, Bernard , Zaffaroni, Daniela , Barile, Monica, Bernard, Loris, Viel, Alessandra , Giannini, Giuseppe , Varesco, Liliana , Radice, Paolo , Greene, Mark H. , Mai, Phuong L., Easton, Douglas F., Chenevix‐Trench, Georgia , Offit, Kenneth, Simard, Jacques , Durocher, Francine , Eccles, Diana , Thorne, Heather , Phillips, Kelly‐Anne , Couch, Fergus J. , Beesley, Jonathan , Chen, Xiaoqing, Wang, Xianshu , Lee, Andrew , Domchek, Susan M. , Gronwald, Jacek , Benı́tez, Javier , Wijnen, Juul , Eccles, Diana M., Cook, Jackie A , Morrison, Patrick J. , Kennedy, M. John, Godwin, Andrew K. , Stoppa‐Lyonnet, Dominique , Caron, Olivier , Pujol, Pascal , Buys, Saundra S. , Chung, Wendy K. , Hopper, John L. , Singer, Christian F. , Robson, Mark E. , Phillips, Kelly, Toland, Amanda Ewart , Agata, Simona , Isaacs, Claudine , Pharoah, Paul D.P. , Karlan, Beth Y. , Meindl, Alfons , Varon-Mateeva, Raymonda, Caldes, Trinidad, Tischkowitz, Marc D. , Neuhausen, Susan L. , Mai, Phuong L., Nevanlinna, H , Caligo, Maria A , Peterlongo, Paolo , Ramus, Susan J , Spurdle, Amanda B , Teo, Soo H , van Rensburg, Elizabeth J , Eccles, Diana , de la Hoya, Miguel , Diez, Orland , Radice, Paolo , Adlard, Julian , Arnold, Norbert , Brunet, Joan , Eeles, Rosalind A , Ehrencrona, Hans , Evans, D Gareth , John, Esther M , Joseph, Vijai , Southey, Melissa C , Jakubowska, Anna , Muranen, Taru A , Nathanson, Katherine L , Arason, Adalgeir , Barrowdale, Daniel , Engel, Christoph , Lazaro, Conxi , Montagna, Marco , Viel, Alessandra , Simard, Jacques , Chenevix-Trench, Georgia , Huzarski, Tomasz , Feliubadaló, Lidia , Hansen, Thomas van Overeem , Manoukian, Siranoush , Lubinski, Jan , Phillips, Kelly-Anne , Terry, Mary Beth , Kwong, Ava

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 29, 2012 | Volume: 21 | Issue: 4 | Pages: 645-657

10.1158/1055-9965.epi-11-0888 | PMID 22351618 Get It

Abstract Background: Genome-wide association studies (GWAS) identified variants at 19p13.1 and ZNF365 (10q21.2) as risk factors for breast cancer among BRCA1 and BRCA2 mutation carriers, respectively. We explored associations with ovarian cancer and with breast cancer by tumor histopathology for these variants in mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Methods: Genotyping data for 12,599 BRCA1 and 7,132 BRCA2 mutation carriers from 40 studies were combined. Results: We confirmed associations between rs8170 at 19p13.1 and breast cancer risk for BRCA1 mutation carriers [HR, 1.17; 95% confidence interval (CI), 1.07–1.27; P = 7.42 × 10−4] and between rs16917302 at ZNF365 (HR, 0.84; 95% CI, 0.73–0.97; P = 0.017) but not rs311499 at 20q13.3 (HR, 1.11; 95% CI, 0.94–1.31; P = 0.22) and breast cancer risk for BRCA2 mutation carriers. Analyses based on tumor histopathology showed that 19p13 variants were predominantly associated with estrogen receptor (ER)-negative breast cancer for both BRCA1 and BRCA2 mutation carriers, whereas rs16917302 at ZNF365 was mainly associated with ER-positive breast cancer for both BRCA1 and BRCA2 mutation carriers. We also found for the first time that rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for BRCA1 (HR, 1.16; 95% CI, 1.05–1.29; P = 3.8 × 10−4) and BRCA2 mutation carriers (HR, 1.30; 95% CI, 1.10–1.52; P = 1.8 × 10−3). Conclusions: 19p13.1 and ZNF365 are susceptibility loci for ovarian cancer and ER subtypes of breast cancer among BRCA1 and BRCA2 mutation carriers. Impact: These findings can lead to an improved understanding of tumor development and may prove useful for breast and ovarian cancer risk prediction for BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev; 21(4); 645–57. ©2012 AACR.
Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase
Sonbol, Mohamad Bassam , Yadav, Hemang, Vaidya, Rakhee , Rana, Vishal , Witzig, Thomas E. , Sonbol, Mohamad B

Mayo Clinic

American Journal of Hematology | March 12, 2012 | Volume: 88 | Issue: 2 | Pages: 152-154

10.1002/ajh.23182 | PMID 22573495 Get It

Common Variation in Nemo-Like Kinase Is Associated with Risk of Ovarian Cancer
Stevens, Kristen N., Kelemen, Linda E., Vierkant, Robert A. , Fredericksen, Zachary, Armasu, Sebastian M. , Tsai, Ya-Yu, Narod, Steven A., Phelan, Catherine M., Sutphen, Rebecca , Birrer, Michael J. , Schildkraut, Joellen M. , Sellers, Thomas A. , Goode, Ellen L. , Purrington, Kristen S. , Wang, Xianshu , Fridley, Brooke L. , Berchuck, Andrew , Couch, Fergus J. , Vierkant, Robert A , Purrington, Kristen S

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 7, 2012 | Volume: 21 | Issue: 3 | Pages: 523-528

10.1158/1055-9965.epi-11-0797 | PMID 22253297 Get It

Abstract Background: Overexpression of mitotic kinases has been associated with prognosis, histologic grade, and clinical stage in ovarian cancer, but the relationship between inherited variation in these genes and ovarian cancer risk has not been well defined. Methods: We measured associations between 397 single nucleotide polymorphisms (SNPs) from 67 mitotic kinases and invasive epithelial ovarian cancer risk in two case–control studies (n = 671 cases; n = 939 controls). Thirty-six candidate SNPs (P < 0.05) were assessed in a replication analysis consisting of three additional studies (n = 1,094 cases; n = 829 controls). Results: In initial analysis, thirty-six SNPs were suggestive of association with risk of serous ovarian cancer, all subtypes of ovarian cancer, or both (P < 0.05). Replication analyses suggested an association between rs2125846 in the Nemo-like kinase (NLK) gene and ovarian cancer (serous OR = 1.36, 95% CI: 1.11–1.67, P = 1.77 × 10−3; all subtypes OR = 1.30, 95% CI: 1.08–1.56, P = 2.97 × 10−3). Furthermore, rs2125846 was associated with risk in the combined discovery and replication sets (serous OR = 1.33, 95% CI: 1.15–1.54; all subtypes OR = 1.27, 95% CI: 1.12–1.45). Conclusions: Variation in NLK may be associated with risk of invasive epithelial ovarian cancer. Further studies are needed to confirm and understand the biologic relationship between this mitotic kinase and ovarian cancer risk. Impact: An association between SNPs in NLK and ovarian cancer may provide biologic insight into the development of this disease. Cancer Epidemiol Biomarkers Prev; 21(3); 523–8. ©2012 AACR.
Gene Set Analysis of Survival Following Ovarian Cancer Implicates Macrolide Binding and Intracellular Signaling Genes
Jenkins, Gregory D. , Tsai, Ya-Yu, Song, Honglin , Bolton, Kelly L. , Fenstermacher, David, Ramus, Susan J. , Cunningham, Julie M. , Vierkant, Robert A. , Chen, Zhihua , Chen, Y. Ann , Iversen, Ed , Menon, Usha , Schildkraut, Joellen M. , Sutphen, Rebecca , Gayther, Simon A. , Hartmann, Lynn C. , Sellers, Thomas A. , Goode, Ellen L. , Fridley, Brooke L. , Tyrer, Jonathan P. , Gentry‐Maharaj, Aleksandra , Pharoah, Paul D.P. , Ramus, Susan J , Vierkant, Robert A , Menon, Usha , Bolton, Kelly L

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 7, 2012 | Volume: 21 | Issue: 3 | Pages: 529-536

10.1158/1055-9965.epi-11-0741 | PMID 22302016 Get It

Abstract Background: Genome-wide association studies (GWAS) for epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy, have identified novel susceptibility loci. GWAS for survival after EOC have had more limited success. The association of each single-nucleotide polymorphism (SNP) individually may not be well suited to detect small effects of multiple SNPs, such as those operating within the same biologic pathway. Gene set analysis (GSA) overcomes this limitation by assessing overall evidence for association of a phenotype with all measured variation in a set of genes. Methods: To determine gene sets associated with EOC overall survival, we conducted GSA using data from two large GWAS (N cases = 2,813, N deaths = 1,116), with a novel Principal Component-Gamma GSA method. Analysis was completed for all cases and then separately for high-grade serous histologic subtype. Results: Analysis of the high-grade serous subjects resulted in 43 gene sets with P < 0.005 (1.7%); of these, 21 gene sets had P < 0.10 in both GWAS, including intracellular signaling pathway (P = 7.3 × 10−5) and macrolide binding (P = 6.2 × 10−4) gene sets. The top gene sets in analysis of all cases were meiotic mismatch repair (P = 6.3 × 10−4) and macrolide binding (P = 1.0 × 10−3). Of 18 gene sets with P < 0.005 (0.7%), eight had P < 0.10 in both GWAS. Conclusion: This research detected novel gene sets associated with EOC survival. Impact: Novel gene sets associated with EOC survival might lead to new insights and avenues for development of novel therapies for EOC and pharmacogenomic studies. Cancer Epidemiol Biomarkers Prev; 21(3); 529–36. ©2012 AACR.
Iatrogenic Aortic Dissection … or Intramural Hematoma?
Welch, Terrence D., Foley, Thomas A. , Barsness, Gregory W. , Spittell, Peter C., Tilbury, R. Thomas, Enriquez‐Sarano, Maurice , Evangelista, Artur , Park, Soon J., Michelena, Héctor I. , Enriquez-Sarano, Maurice

Mayo Clinic

Circulation | March 6, 2012 | Volume: 125 | Issue: 9 | Pages: No page available

10.1161/circulationaha.111.056937 | PMID 22392868 Get It

Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine
Lindblad, A. S., Harrington, Molly, Mathew, N. T., Hirtz, Deborah, Silberstein, Stephen D. , Dodick, David W. , Holroyd, Kenneth J.

Mayo Clinic

Neurology | March 1, 2012 | Volume: 78 | Issue: 13 | Pages: 976-984

10.1212/wnl.0b013e31824d5846 | PMID 22377815 Get It